Hengrui Medicine’s progress announcement on the repurchase of the company’s A shares
Securities code: 600276 Securities abbreviation: Hengrui Medicine Announcement number: Lin 2026-082
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Announcement on the progress of repurchasing the company’s A shares
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The first disclosure date of the repurchase plan is 2025/8/21
The implementation period of the buyback plan is August 20, 2025 ~ August 19, 2026
Estimated repurchase amount: 1 million yuan to 2 million yuan
□Reduce registered capital
√Used for employee stock ownership plans or equity incentives
Repurchase purpose
□Used to convert company convertible bonds
□To protect the company’s value and shareholders’ rights and interests
The cumulative number of shares repurchased is 12.0562 million shares
The cumulative number of shares repurchased accounts for 0.18% of the total share capital.
The cumulative repurchased amount is 771.9809 million yuan
Actual repurchase price range: 53.52 yuan/share~70.00/yuan/share
1. Basic information on share repurchase
Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 18th meeting of the ninth board of directors on August 20, 2025, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's A Shares through Centralized Bidding Transactions", agreeing that the company will use its own funds to repurchase the company's shares through centralized bidding transactions for the implementation of the A-share employee stock ownership plan. The repurchase price shall not exceed RMB 90.85 per share (inclusive), and the total repurchase funds shall not be less than RMB 1 billion and shall not exceed RMB 2 billion. The repurchase period is within 12 months from the date the board of directors considers and approves the share repurchase plan. For details, please refer to the "Repurchase Report on the Repurchase of the Company's A Shares through Centralized Bidding Transactions" (Announcement No.: Lin 2025-130) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn).
2. Progress of share repurchase
According to the relevant provisions of the "Share Repurchase Rules of Listed Companies" and "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares", listed companies should announce the progress of repurchases as of the end of the previous month within the first three trading days of each month. The progress of the company’s share repurchase is now announced as follows:
In May 2026, the company repurchased 0 shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. As of May 31, 2026, the company's share repurchase plan has repurchased a total of 12.0562 million shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. The repurchased shares accounted for 0.18% of the company's total share capital. The highest purchase price was RMB 70.00 per share and the lowest price was RMB 53.52 per share. The total amount paid was RMB 77,198.09. Ten thousand yuan (excluding transaction fees).
The above-mentioned repurchase complies with the provisions of relevant laws and regulations and the company's established share repurchase plan.
3. Other matters
The company will strictly abide by the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, make repurchase decisions based on market conditions during the repurchase period and implement them. At the same time, it will perform information disclosure obligations in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.
June 2, 2026